Treatment Refractory Type 2 Diabetes Mellitus — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for treatment refractory type 2 diabetes mellitus. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
4
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Treatment Refractory Type 2 Diabetes Mellitus

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sanofi 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating treatment refractory type 2 diabetes mellitus. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
27
2
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Amaryl
GLIMEPIRIDE
 Sanofi 4 63 — 2027-01-30

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7700128 Amaryl formulation 65 2027-01-30
7700128 Amaryl formulation 65 2027-01-30
8071130 Amaryl formulation 60 2028-06-08
8071130 Amaryl formulation 60 2028-06-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8071130 Amaryl formulation 60 2028-06-08
8071130 Amaryl formulation 60 2028-06-08
7700128 Amaryl formulation 65 2027-01-30
7700128 Amaryl formulation 65 2027-01-30

Related